SBI-993_product_DataBase

Bioactivity	SBI-993 is a SBI-477 analog with improved potency and suitable pharmacokinetic properties for in vivo bioavailability. SBI-993 stimulates insulin signaling by deactivating the transcription factor MondoA[1].
Invitro	SBI-993 reduces thioredoxin-interacting protein (TXNIP) and arrestin domain-containing 4 (ARRDC4) expression in human myotubes[1].
In Vivo	SBI-993 (50 mg/kg; s.c.; daily; for 7 days) treatment reduces the expression of triacylglyceride synthesis and lipogenic genes in both muscle and liver. SBI-993 also reduces Txnip and Arrdc4 expression. And ccupation of both ChREBP and MondoA on the Txnip and pyruvate kinase (Pklr) gene promoters is reduced in liver by SBI-993[1].SBI-993 improves insulin signaling in both muscle and liver following an acute insulin challenge[1]. Animal Model:
Name	SBI-993
CAS	2073059-82-0
Formula	C23H24N4O4S
Molar Mass	452.53
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Reference	[1]. Byungyong Ahn, et al. MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling. J Clin Invest. 2016 Sep 1;126(9):3567-79.

PeptideDB